Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2023-02-14 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
MYX announces US launch of Diltiazem ER and Doryx MPC 60mg 1
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement about the US launch of two new pharmaceutical products by Mayne Pharma. It contains no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. The content is a straightforward corporate announcement about product launches, which fits best under Capital/Financing Update (CAP) as it relates to business development and product portfolio expansion. The document length is short (2500 characters), and it is not a report or a notice of report publication. Therefore, the most appropriate classification is CAP with high confidence.
2023-02-14 English
Notification of cessation of securities - MYX 4 pages 184.9KB
Regulatory Filings Classification · 100% confidence The document is an Appendix 3H form, which is a notification to the ASX regarding the cessation of securities. It details the cessation of shares due to an employee share scheme buy-back, including the number of securities ceased, the reason for cessation, and the issued capital following the changes. The document is regulatory in nature, providing a formal announcement to the stock exchange about changes in securities but does not contain financial statements or detailed financial performance data. It is not an annual report, earnings release, or management report. It is a specific regulatory filing related to securities cessation and buy-back notification under ASX listing rules. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-01-24 English
Update - Notification of buy-back - MYX 6 pages 27.1KB
Transaction in Own Shares Classification · 100% confidence The document is titled 'Notification of buy-back' and repeatedly references details about a share buy-back by Mayne Pharma Group Limited. It includes specifics such as the number of securities bought back, the type of buy-back (employee share scheme buy-back), dates, and consideration paid. There is no indication of financial statements, earnings data, or management discussion. The content is focused on the company's repurchase of its own shares, which aligns with the category for share repurchase or issuance activities. Therefore, the document fits the 'Transaction in Own Shares' category (POS). The document length and detail confirm it is the actual notification, not just an announcement of a report publication or a regulatory filing.
2023-01-17 English
US launch of HALOETTE, a generic version of NUVARING 2 pages 208.1KB
Regulatory Filings Classification · 95% confidence The document is a joint press release announcing the US launch of HALOETTE, a generic contraceptive product. It contains no financial statements, regulatory filings, or detailed financial data. It is a corporate announcement about a product launch, not a report or regulatory filing. The document length is 4689 characters, which is relatively short and typical for a press release. There is no indication of shareholder meeting materials, financial results, or management changes. Therefore, the document fits best into the category of a general regulatory announcement or corporate news release, which corresponds to Regulatory Filings (RNS).
2023-01-12 English
Mayne Pharma provides update on capital management timeline 3 pages 151.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Mayne Pharma providing an update on the timetable for capital management initiatives. It discusses changes to the timing of a capital return, special dividend, share consolidation, and financing arrangements. The content focuses on corporate actions related to capital management, including dividends, share consolidation, and financing updates. There are no detailed financial statements or comprehensive financial performance data presented, which would be expected in an Annual Report (10-K) or Interim Report (IR). The document is not a call transcript, audit report, or legal proceeding update. It is clearly an update on capital management activities, including dividend and share consolidation timing, and financing arrangements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8914 characters) and detailed content support this classification with high confidence.
2023-01-11 English
JP Morgan Healthcare Conference Presentation 18 pages 969.6KB
Investor Presentation Classification · 95% confidence The document is a detailed company presentation from Mayne Pharma Group Limited for the JP Morgan Healthcare Conference dated January 2023. It includes strategic priorities, product portfolio summaries, market positioning, and investment rationale. The text explicitly mentions that a copy of the presentation is attached and that it is intended for investor update purposes. There are no financial statements or detailed financial results presented, nor is this a regulatory filing or announcement of voting results. The content is consistent with an Investor Presentation, which focuses on financials, strategy, and market position for investors. The document length (15,000 characters) and detailed content support this classification rather than a brief announcement or a full annual/interim report.
2023-01-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.